50
Participants
Start Date
November 14, 2022
Primary Completion Date
December 1, 2026
Study Completion Date
December 1, 2027
GEM/DOX + TGFBi expanded NK cells
"8 cycles consisting of gemcitabine, docetaxel, supportive dexamethasone and pegfilagrastim, and universal donor, TGFBi ex vivo expanded NK cells~* Each cycle will be repeated every 21 days based upon disease response and toxicity criteria~* Tumor response assessed after Cycles 2, 4, 6, and 8~ 1. Gemcitabine 675mg/m2/dose IV on Days 1 and 8~ 2. Docetaxel 75mg/m2/dose IV on Day 8~ 3. Dexamethasone 3mg/m2/dose (max 8 mg/dose) PO BID on Days 7, 8, and 9~ 4. Pegfilgrastim (Peg-GCSF) 0.1mg/kg/dose (max 6 mg/dose) SQ on Day 9~ 5. NK cells 1 x 10e8 cells/kg/dose IV on Day 12 (+ 1-2 days)"
RECRUITING
Montefiore Medical Center, The Bronx
RECRUITING
Roswell Park Comprehensive Cancer Center, Buffalo
RECRUITING
Children's Hospital of Philadelphia, Philadelphia
RECRUITING
Duke Children's Hospital/Duke Health, Durham
RECRUITING
Levine Cancer Institute, Charlotte
RECRUITING
Nemours Jacksonville, Jacksonville
RECRUITING
University of Florida, Gainesville
RECRUITING
University of Miami, Miami
RECRUITING
Johns Hopkins All Children's Hospital, St. Petersburg
RECRUITING
University of Alabama, Birmingham
RECRUITING
Nationwide Children's Hospital, Columbus
RECRUITING
Washington University/St Louis Childrens, St Louis
RECRUITING
UT Southwestern, Dallas
RECRUITING
University of Texas MD Anderson Cancer Center, Houston
RECRUITING
Primary Children's Hospital, Salt Lake City
RECRUITING
Children's Hospital of Los Angeles, Los Angeles
National Pediatric Cancer Foundation
OTHER
Nationwide Children's Hospital
OTHER